The efficiency and tolerability of lacosamide therapy in adolescents and adults with new-onset focal epilepsy in terms of the epileptiform activity index
https://doi.org/10.14412/2074-2711-2020-3-56-62
Abstract
Lacosamide (LCM) is one of the most promising antiepileptic drugs (AEDs) for focal epilepsy (FE); however, in Russia there are only a few works devoted to its practical application.
Objective: to evaluate the efficiency of LCM therapy in adolescents and adults with new-onset FE.
Patients and methods. The investigation enrolled 36 patients aged 16-78 years. All the patients underwent video-ECG monitoring with quantification of the epileptiform activity index (EAI) at baseline and 1, 3, 6 and 12 months of treatment. The treatment efficiency was evaluated using the standard measures: drug-induced remission, a response rate of ≥50%, an insufficient efficiency of ≤50%, higher seizure frequency, and therapy retention rates. Adverse events (AEs) were assessed using the SIDe-effects of AntiEpileptic Drugs (SIDAED) questionnaire.
Results and discussion. Just 3 months after starting treatment, the total EAI substantially decreased from 2.92 [0; 6.7] to 1.95 [0; 3.07] (p<0.05). LCM demonstrated a high efficacy and a good tolerance in the therapy of FE: by the end of 12-month follow-up, there was a considerable decrease in EAI by 1.57 times (p<0.05); the LCM monotherapy retention rate of 72.2% was achieved in 26 patients: 20 (55.6%) patients had drug-induced remission; six (16.7%) patients were responders. AEs were recorded in 5 (13.8%) cases.
Conclusion. LCM is an effective AED for the initial monotherapy of FE. The use of LCM in FE causes a considerable decrease in EAI by 1.57 times (p<0.05).
Supporting agencies: This article has been supported by UCB Pharma S.A. The sponsor has participated in the development of the investigation project and supported the investigation program, as well as in the decision to submit the article for publication.
About the Authors
V. A. Karlov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
20, Delegatskaya St., Build. 1, Moscow 127473.
Competing Interests:
The conflict of interest has not affected the results of the investigation.
P. N. Vlasov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
Pavel Nikolaevich Vlasov.
20, Delegatskaya St., Build. 1, Moscow 127473.
Competing Interests:
The conflict of interest has not affected the results of the investigation.
A. B. Kozhokaru
A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia,
Russian Federation
Competing Interests:
Russian Federation
23, Marshal Novikov St., Moscow123098.
Competing Interests:
The conflict of interest has not affected the results of the investigation.
A. S. Samoilov
A.I. Burnazyan Federal Medical Biophysical Center, Federal Biomedical Agency of Russia,
Russian Federation
Competing Interests:
Russian Federation
23, Marshal Novikov St., Moscow123098.
Competing Interests:
The conflict of interest has not affected the results of the investigation.
A. S. Orlova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Competing Interests: The conflict of interest has not affected the results of the investigation.
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991.
Competing Interests: The conflict of interest has not affected the results of the investigation.
References
1. De Biase S, Gigli GL, Valente M, et al. Lacosamide for the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3): 459-68. doi: 10.1517/17425255.2014.883378. Epub 2014 Jan 30.
2. Glauser T, Ben-Menachem E, Bourgeois B, et al.; ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013 Mar;54(3):551-63. doi: 10.1111/epi.12074. Epub 2013 Jan 25.
3. Karlov VA. Epilepsiya u detei i vzroslykh, zhenshchin i muzhchin. Rukovodstvo dlya vrachei. 2-e izdanie [Epilepsy in children and adults, women and men. Doctor's guide. 2nd edition]. Moscow: BINOM; 2019. 896 p.
4. Brodie MJ, Sills GJ. Combining antiepileptic drugs — Rational polytherapy? Seizure. 2011 Jun; 20(5):369-75. doi: 10.1016/j.seizure.2011.01.004. Epub 2011 Feb 8.
5. Avakyan GN. Questions of modern epileptology. Epilepsiya i paroksizmal'nye sostoyaniya. 2015;7(4):16-21. (In Russ.).
6. Beghi E. Addressing the burden of epilepsy: Many unmet needs. Pharmacol Res. 2016 May; 107:79-84. doi: 10.1016/j.phrs.2016.03.003. Epub 2016 Mar 4.
7. Noe K. Counseling and Management of the Risks of Living With Epilepsy. Continuum (Minneap Minn). 2019 Apr;25(2):477-91. doi: 10.1212/CON.0000000000000708.
8. Verrier RL, Pang TD, Nearing BD, Schachter SC. The Epileptic Heart: Concept and clinical evidence. Epilepsy Behav. 2020 Apr;105:106946. doi: 10.1016/j.yebeh.2020.106946. Epub 2020 Feb 25.
9. Pylaeva OA, Mukhin KYu, Mironov MB. Efficacy and tolerability of lacosamide (Vimpat) in the treatment of epilepsy in adults (literature review). Russkii zhurnal detskoi nevrologii. 2014; 9(4):59-68. (In Russ.).
10. Rogawski MA, Tofighy A, White HS, et al. Current understanding of the mechanism of action of the antiepileptic drug lacosamide. Epilepsy Res. 2015 Feb;110:189-205. doi: 10.1016/j.eplepsyres.2014.11.021. Epub 2014 Dec 3.
11. Wilson SM, Khanna R. Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol. 2015 Apr;51(2):599-609. doi: 10.1007/s12035-014-8775-9. Epub 2014 Jun 20.
12. Lebedeva AV, Burd SG, Belyaev OV, et al. Russian experience of use of lacosamide (Vimpat) in the treatment of patients with uncontrolled focal epilepsy. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016;116(9-2): 74-81. (In Russ.).
13. Villanueva V, Giraldez BG, Toledo M, et al. Lacosamide monotherapy in clinical practice: A retrospective chart review. Acta Neurol Scand. 2018 Sep;138(3):186-194. doi: 10.1111/ane.12920. Epub 2018 Mar 14.
14. Mukhin KYu, Tysyachina MD, Glukhova LYu, Freidkova NV. A clinical case of use of lacosamide (Vimpat) in the treatment of a resistant form of symptomatic focal epilepsy. Russkii zhurnal detskoi nevrologii. 2011;6(2): 38-42. (In Russ.).
15. Mironov MB, Mukhin KYu, Pylaeva OA. Efficacy of vimpat (lacosamide) in a patient with a resistant form of cryptogenic focal epilepsy with focal auto-motor and secondary generalized seizures (case description). Russkii zhurnal detskoi nevrologii. 2012;7(2):3-12. (In Russ.).
16. Rudakova IG, Vlasov PN, Lipatova LV, Voronkova KV. Lacosamide (vimpat). Prospects for clinical application. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2017;117(9): 147-52. (In Russ.).
17. Yakovleva YuA, Yanaeva AN, Spikina AA, Rukavitsyna EL. Use of lacosamide in patients with focal epilepsy and comorbid psychiatric disorders. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(10-2):98-104. (In Russ.).
18. Litvinova CA, Avakyan GG, Nerobkova LN, et al. Influence of lacosamide on epileptiform activity and dynamics of structural and functional connections of the epileptic system of rats with chronic focal epilepsy. Epilepsiya i paroksiz-mal'nye sostoyaniya. 2019;11(1):37-45. (In Russ.).
19. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4): 475-82. doi: 10.1111/epi.12550. Epub 2014 Apr 14.
20. Uijl SG, Uiterwaal CS, Aldenkamp A, et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure. 2006 Jun;15(4):242-8. doi: 10.1016/j.seizure.2006.02.009. Epub 2006 Mar 23.
21. Resolution of the meeting of experts of the working group of the Russian Antiepileptic League (March 5, 2019, Moscow). Epilepsiya i paroksizmal'nye sostoyaniya. 2019;11(1): 97-100. (In Russ.).
22. Vlasov PN, Kamel'kova EG, Drozhzhina GR. Efficacy and tolerance of intravenous lacosamide in urgent neurological situations. Nevrologiya neiropsikhiatriya psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(1S):60-3. (In Russ.). doi:10.14412/2074-2711-2012-2501
23. Davidson KE, Newell J, Alsherbini K, et al. Safety and Efficiency of Intravenous Push Lacosamide Administration. Neurocrit Care. 2018 Dec;29(3):491-495. doi: 10.1007/s12028-018-0560-6.
24. Rosenow F, Brandt C, Bozorg A, et al. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol Scand. 2020 Jun;141(6):473-482. doi: 10.1111/ane.13230. Epub 2020 Mar 13.
25. Bochanova EN, Shnaider NA, Dmitrenko DV, et al. Comparative assessment of the frequency of aggravation of epileptic seizures against the background of taking antiepileptic drugs of different generations. Farmateka. 2017;(9): 56-60. (In Russ.).
Review
For citations:
Karlov VA, Vlasov PN, Kozhokaru AB, Samoilov AS, Orlova AS. The efficiency and tolerability of lacosamide therapy in adolescents and adults with new-onset focal epilepsy in terms of the epileptiform activity index. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(3):56-62. https://doi.org/10.14412/2074-2711-2020-3-56-62
Views:
822
Email this article 